Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 126 | 2 | 127 | +3 |
| Shares | 107.1M | 515.6K | 109.4M | +2.74M (+2.6%) |
| Value | $53.8M | $259.1K | $49.7M | −$3.89M (−7.3%) |
2 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nuveen, LLC | 515,445 | $232.8K | 0.00% |
| Cookson Peirce & Co Inc | 250,000 | $112.9K | 0.01% |
| HRT Financial LP | 208,918 | $94.0K | 0.00% |
| ORG Partners LLC | 115,400 | $47.4K | 0.01% |
| Intech Investment Management LLC | 50,922 | $23.0K | 0.00% |
| Zacks Investment Management | 45,692 | $20.6K | 0.00% |
| XTX Topco Ltd | 43,178 | $19.5K | 0.00% |
| AQR Capital Management LLC | 31,991 | $14.4K | 0.00% |
| Private Advisor Group, LLC | 20,058 | $9.06K | 0.00% |
| Chapin Davis, Inc. | 20,029 | $9.04K | 0.00% |
| Integrity Alliance, LLC. | 20,000 | $9.03K | 0.00% |
| Founders Capital Management | 12,000 | $5.42K | 0.00% |
| R Squared Ltd | 11,150 | $5.04K | 0.01% |
| Larson Financial Group LLC | 10,000 | $4.52K | 0.00% |
| Wolff Wiese Magana LLC | 1,000 | $452 | 0.00% |
| Farther Finance Advisors, LLC | 429 | $176 | 0.00% |
| EverSource Wealth Advisors, LLC | 111 | $50 | 0.00% |
| True Wealth Design, LLC | 96 | $44 | 0.00% |
| Rossby Financial, LCC | 58 | $28 | 0.00% |
Sold out (16)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Perceptive Advisors LLC | 7,236,843 | $3.64M |
| Alyeska Investment Group, L.P. | 3,947,369 | $1.98M |
| Jacobs Levy Equity Management, Inc | 1,033,763 | $519.5K |
| Prescott General Partners LLC | 386,000 | $194.0K |
| DCF Advisers, LLC | 107,751 | $54.1K |
| Atria Wealth Solutions, Inc. | 57,423 | $28.9K |
| United Bank | 12,000 | $6.03K |
| Thrivent Financial for Lutherans | 10,000 | $5.00K |
| Asset Planning,Inc | 2,036 | $1.02K |
| Sugar Maple Asset Management, LLC | 1,000 | $503 |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 300 | $150 |
| Coppell Advisory Solutions LLC | 63 | $31 |
| FLP Wealth Management, LLC | 50 | $25 |
| Plante Moran Financial Advisors, LLC | 2 | $1 |
| Lazard Asset Management LLC | 148 | $0 |
| Simplex Trading, LLC | 351 | $0 |
Not filed for Q1 2025 yet (2)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 515,445 | $259.0K |
| RE Dickinson Investment Advisors, LLC | 205 | $100 |